In this open‑label proof‑of‑concept study, the first four participants with alcohol use disorder tolerated an 8‑week MDMA‑assisted psychotherapy programme (two MDMA sessions each) with no MDMA‑related serious adverse events or clinically significant physiological, ECG or laboratory changes, supporting safety and informing plans for a randomised placebo‑controlled trial.
- Published
- Journal
- BMJ Case Reports
- Authors
- Sessa, B., Sakal, C., O'Brien S., Nutt, D. J.